Results 81 to 90 of about 2,265 (188)

Dupilumab: A new paradigm for the treatment of allergic diseases [PDF]

, 2018
Moderate and severe forms of allergic diseases such as atopic dermatitis and asthma are a challenge for clinicians. In these conditions, which severely affect the quality of life of the patient and frequently have associated allergic comorbidities, the ...
Dávila, Ignacio, Sastre, Joaquín
core   +2 more sources

Interleukin (IL)‐5, Eosinophils and IL‐5 Pathway Inhibitors in Eosinophilic Granulomatosis with Polyangiitis.

Arthritis &Rheumatology, Accepted Article.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Positioning of Tezepelumab in Severe Asthma

Journal of Investigational Allergology and Clinical Immunology
Asthma is one of the most common chronic diseases and is estimated to be severe in 3%-10% of affected patients. There is a need for additional biologic treatments that are highly efficacious across the spectrum of severe uncontrolled asthma. Currently available drugs inhibit 1 or 2 specific cytokines or IgE antibodies and thus only partially suppress ...
J C, Miralles-López, D, Antolín-Amérigo, I, García-Moguel, J, Domínguez-Ortega, J, Delgado-Romero, S, Quirce   +5 more
openaire   +2 more sources

Identifying Therapeutic Targets for Bronchial Asthma: Systematic Druggable Genome‐Wide Mendelian Randomization

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background The treatment and prevention of bronchial asthma continue to present significant challenges. Mendelian randomization (MR) has been extensively employed to identify novel therapeutic targets. Consequently, we conducted a systematic MR analysis across the druggable genome to identify potential therapeutic targets for asthma.
Haijiao Wang, Peng Zhang, Hongpeng Yu, Li Shi, Tan Wang   +4 more
wiley   +1 more source

Three-dimensional bronchial tree visualization in exercise-induced severe asthma following tezepelumab treatment

Journal of Allergy and Clinical Immunology: Global
Airway hyperresponsiveness, a key feature of asthma, is associated with exercise-induced asthma. Tezepelumab was reported to reduce airway hyperresponsiveness.
Yoshiro Kai, MD, PhD, Yuichi Hishida, RT
doaj   +1 more source

Molecular IgE Sensitization Profiling With Micro‐Arrayed Allergen Molecules in Adult Patients With Asthma From the LEAD Cohort: A Precision Medicine Approach

Allergy, Volume 81, Issue 1, Page 130-144, January 2026.
In the LEAD cohort, micro‐arrayed asthma allergens identified IgE‐sensitized adult asthma patients. Compared to non‐IgE‐sensitized patients, they had better lung function, took less ICS and had lower eosinophils. IgE‐sensitized patients were sensitized to a handful of respiratory allergen sources and may benefit from allergen‐specific forms of ...
Huey‐Jy Huang, Robab Breyer‐Kohansal, Katarzyna Niespodziana, Charmaine J. M. Lim, Marie‐Kathrin Breyer, Rudolf Valenta, Sylvia Hartl, the Allergochip Working Group, Maria‐Roxana Buzan, Kuan‐Wei Chen, Monica Daniela Cotarcă, Alexandra Dubovets, Pia Gattinger, Alexander Karaulov, Evgenii Kozlov, Carmen Panaitescu, Daria Trifonova, Mikhail Tulaev, Susanne Vrtala, Milena Weber, Lauriana‐Eunice Zbîrcea   +20 more
wiley   +1 more source

Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta‐Analysis

Allergy, Volume 81, Issue 1, Page 24-55, January 2026.
ABSTRACT Biologics are effective for severe asthma, but not all patients benefit equally. There is an urgent need to understand which biologic works best for which patient. We systematically searched for predictors of response to biologics (except omalizumab) for severe asthma in four bibliographic databases and two trial registries from 1990 to 2024 ...
Anna Rattu, Piers Dixey, David Charles, Chris Brightling, Kian Fan Chung, Apostolos Bossios, Arnaud Bourdin, Ratko Djukanovic, Sven‐Erik Dahlén, Louise Fleming, Rekha Chaudhuri, Erik Melén, Antoine Deschildre, Charles Pilette, Gerard H. Koppelman, Andrew Exley, Freja Anckers, Sarah Miller, Hanna Nielsen, Clare Williams, Ekaterina Khaleva, Graham Roberts, on behalf of the 3TR consortium Respiratory Work Package   +22 more
wiley   +1 more source

Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma

Journal of Asthma and Allergy, 2021
Sady Alpizar,1 Ayman Megally,2 Claudia Chen,3 Abhi Raj,4 John Downie,5 Gene Colice2 1Clinical Research Trials of Florida, Inc., Tampa, FL, USA; 2Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD,
Alpizar S, Megally A, Chen C, Raj A, Downie J, Colice G   +5 more
doaj  

Is Efficacy of Tezepelumab Independent of Severe Asthma Phenotype? [PDF]

, 2023
Brusselle, Guy, Riemann, Sebastian
core   +2 more sources

Chronic obstructive pulmonary disease new pharmacological treatments and their relationship with cardiovascular effects [PDF]

Chronic obstructive pulmonary disease (COPD) is considered a progressive inflammatory condition that is often complicated by one or more cardiovascular diseases (CVD). This review explores the cardiovascular impacts of current anti-inflammatory therapies
Dávil, Luis P., Espinosa, Alisson Valladares, Guillen Gallardo, Erika, Loaiza, Francisca A., Pérez, Deysi Carolina Silva, Torres, André Valenzuela, Vásquez, Johanna Lisbeth   +6 more
core   +2 more sources